India Deliberates Orphan Rules
This article was originally published in PharmAsia News
India is deliberating a string of initiatives to ensure that drugs for rare diseases reach patients faster and are available at "reasonable" prices in the country.
You may also be interested in...
India appears to be on course to developing a national rare disease policy, with the adoption of a specific definition for rare diseases and the initiation of a rare disease registry in the country.
Biocon sees some wins for biosimilar adalimumab in the US and signals more opportunities amid the slower than anticipated build-out for Humira rivals. Chinese competition looms for glargine, but the Indian company declares it “will be competitive if these folks launch.”
India’s National Cancer Grid pilots pooled procurement for 40 drugs including trastuzumab, imatinib, and pemetrexed, delivering median savings of over 80%. Experts discuss with Scrip the prospects of scaling the initiative and what it may mean for pharma’s margins and go-to-market strategy.